MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

79.91
+1.39
+1.77%
Pre Market: 79.91 0 0.00% 08:38 06/14 EDT
OPEN
79.02
PREV CLOSE
78.52
HIGH
79.97
LOW
78.48
VOLUME
1
TURNOVER
--
52 WEEK HIGH
99.00
52 WEEK LOW
35.65
MARKET CAP
3.70B
P/E (TTM)
-43.2273
1D
5D
1M
3M
1Y
5Y
BRIEF-Glaukos Achieves Pipeline Milestone With Completion Of Patient Enrollment In U.S. NDA Phase 3 Clinical Trials For Idose® Tr
reuters.com · 4d ago
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose(R) TR
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomi...
Business Wire · 4d ago
Glaukos Completes Patient Enrollment for Late-Stage Study of iDose TR to Treat High Eye Fluid Pressure in Glaucoma
MT Newswires · 4d ago
Glaukos gets Australia’s TGA regulatory approval for PRESERFLO MicroShunt
Glaukos (GKOS) announces that the Therapeutic Goods Administration ((TGA)) of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure ((IOP)) in eyes of certain patients
Seekingalpha · 6d ago
BRIEF-Glaukos Announces Australia's TGA Regulatory Approval For Preserflo Microshunt
reuters.com · 6d ago
Glaukos Announces Australia's TGA Regulatory Approval for PRESERFLO(TM) MicroShunt
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the Therapeutic Goods Administration (TGA) ...
Business Wire · 6d ago
Glaukos Gets Approval For Glaucoma System in Australia
MT Newswires · 6d ago
Glaukos (GKOS) Down 11.1% Since Last Earnings Report: Can It Rebound?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/04 15:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GKOS. Analyze the recent business situations of Glaukos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GKOS stock price target is 86.50 with a high estimate of 105.00 and a low estimate of 48.00.
EPS
Institutional Holdings
Institutions: 317
Institutional Holdings: 61.85M
% Owned: 133.65%
Shares Outstanding: 46.28M
TypeInstitutionsShares
Increased
71
3.05M
New
36
295.55K
Decreased
79
2.29M
Sold Out
26
247.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.06%
Key Executives
Non-Executive Chairman/Independent Director
William Link
President/Chief Executive Officer/Director
Thomas Burns
Chief Financial Officer/Senior Vice President
Joseph Gilliam
Chief Operating Officer
Chris Calcaterra
Independent Director
Mark Foley
Independent Director
David Hoffmeister
Independent Director
Gilbert Kliman
Independent Director
Marc Stapley
Independent Director
Denice Torres
Independent Director
Aimee Weisner
Independent Director
Leana Wen
No Data
About GKOS
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.